Literature DB >> 12006795

Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study.

Andreas E Triltsch1, Martin Welte, Peter von Homeyer, Jochen Grosse, Arka Genähr, Maryam Moshirzadeh, Alexander Sidiropoulos, Wolfgang Konertz, Wolfgang J Kox, Claudia D Spies.   

Abstract

OBJECTIVE: To compare dexmedetomidine vs. placebo with respect to the amount of additional propofol and morphine used for bispectral index-guided sedation and analgesia in mechanically ventilated, intensive care patients after surgery.
DESIGN: Prospective, randomized, double blind, placebo-controlled, phase II clinical trial.
SETTING: General surgical and cardiac surgical intensive care units. PATIENTS: Thirty patients scheduled for major surgery requiring mechanical ventilation for a minimum of 6 hrs were included in the study.
INTERVENTIONS: Patients were assigned randomly to receive either dexmedetomidine (loading infusion, 6.0 microg x kg(-1) x hr(-1) for 10 mins; maintenance infusion, 0.1-0.7 microg x kg(-1) x hr(-1)) or placebo after intensive care unit admission.
MEASUREMENTS AND MAIN RESULTS: Sedation was guided by using the electroencephalographic parameter bispectral index, a new noninvasive method to estimate the level of sedation. We aimed at maintaining bispectral index ranges between 60 and 70 during mechanical ventilation before starting weaning, 65 and 95 during weaning, and 85 to 95 postextubation. Additional sedative and analgesic medication was given (propofol and morphine) as clinically indicated and within the previously mentioned bispectral index ranges. Patients receiving dexmedetomidine required significantly less propofol during mechanical ventilation (0.87 +/- 0.21 vs. 1.52 +/- 0.30 mg x kg(-1) x hr(-1); p <.01) and weaning (0.17 +/- 0.06 vs. 0.62 +/- 0.21 mg x kg(-1) x hr(-1); p <.001) to maintain the target bispectral index range. During study drug administration, morphine requirements for dexmedetomidine-treated patients were reduced by 58% (p =.05). Hemodynamic stability during weaning and after extubation was better maintained in patients receiving dexmedetomidine.
CONCLUSIONS: Dexmedetomidine reduced propofol requirements and improved hemodynamic stability during bispectral index-guided intensive care unit sedation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006795     DOI: 10.1097/00003246-200205000-00009

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  46 in total

1.  Sedation during noninvasive mechanical ventilation with dexmedetomidine or midazolam: A randomized, double-blind, prospective study.

Authors:  Nimet Senoglu; Hafize Oksuz; Zafer Dogan; Huseyin Yildiz; Hilmi Demirkiran; Hasan Ekerbicer
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

2.  Validity and reliability of the DDS for severity of delirium in the ICU.

Authors:  Hilke Otter; Jörg Martin; Katrin Bäsell; Christian von Heymann; Ortrud Vargas Hein; Patricia Böllert; Pattariya Jänsch; Ina Behnisch; Klaus-Dieter Wernecke; Wolfgang Konertz; Stefan Loening; Jens-Uwe Blohmer; Claudia Spies
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

Review 4.  Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.

Authors:  Derek J Roberts; Babar Haroon; Richard I Hall
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

5.  Acute hemodynamic changes after rapid intravenous bolus dosing of dexmedetomidine in pediatric heart transplant patients undergoing routine cardiac catheterization.

Authors:  E H Jooste; W T Muhly; J W Ibinson; T Suresh; D Damian; A Phadke; P Callahan; S Miller; B Feingold; S E Lichtenstein; J G Cain; C Chrysostomou; P J Davis
Journal:  Anesth Analg       Date:  2010-11-08       Impact factor: 5.108

6.  Electrocardiographic effects of dexmedetomidine in patients with congenital heart disease.

Authors:  Constantinos Chrysostomou; Rukmini Komarlu; Steven Lichtenstein; Dana Shiderly; Gaurav Arora; Richard Orr; Peter D Wearden; Victor O Morell; Ricardo Munoz; Edmund H Jooste
Journal:  Intensive Care Med       Date:  2010-03-06       Impact factor: 17.440

7.  Use of dexmedetomidine in a pediatric heart transplant patient.

Authors:  C Chrysostomou; T Zeballos
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

8.  A comparison of dexmedetomidine sedation with and without midazolam for dental implant surgery.

Authors:  Ryo Wakita; Hikaru Kohase; Haruhisa Fukayama
Journal:  Anesth Prog       Date:  2012

9.  Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects.

Authors:  Yahya Shehabi; Urban Ruettimann; Harriet Adamson; Richard Innes; Mathieu Ickeringill
Journal:  Intensive Care Med       Date:  2004-08-26       Impact factor: 17.440

10.  ICU sedation with dexmedetomidine after severe traumatic brain injury.

Authors:  Stephen S Humble; Laura D Wilson; Taylor C Leath; Matthew D Marshall; Daniel Z Sun; Pratik P Pandharipande; Mayur B Patel
Journal:  Brain Inj       Date:  2016-07-26       Impact factor: 2.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.